Radium-223 dichloride (xofigo)

Ended Awarded Last action

Contract number
36C25019F0071
Awardee
Awarding agency
Obligated
$222,838

Award facts

Contract value 100% obligated
$222,837.89 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Whippany, Hanover, NJ 07981, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00002 · Decrease funding required.otradium-223 dichloride (xofigo) -$87,035
Funding Only Action P00001 · Additional funding required.otradium-223 dichloride (xofigo) $99,941
Original award $209,932

About this award

This contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Bayer Healthcare Pharmaceuticals Inc. to provide RADIUM-223 DICHLORIDE (XOFIGO), a prostate cancer treatment medication, through a Blanket Purchase Agreement (BPA) under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has a potential value of $222,837.89 and a completion date of September 30, 2019. No small business set-aside was used. Bayer Healthcare Pharmaceuticals Inc. is a subsidiary of Bayer AG and a major supplier of pharmaceuticals and medical products to federal government customers, including the VA and the Defense Logistics Agency (DLA). This contract leverages Bayer's FSS pricing to facilitate rapid procurement of essential medical products for veterans, active duty military, and their dependents through the VA health network.

Quick answers

Who was awarded contract 36C25019F0071?

36C25019F0071 was awarded to Bayer Healthcare Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on October 1, 2018.

How much is contract 36C25019F0071 worth?

The government has obligated $222,838 on 36C25019F0071.

Is contract 36C25019F0071 an order under another contract?

Yes. 36C25019F0071 is a BPA call under V797P2202D-VA25114A0051, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36C25019F0071 competed?

The extent of competition for 36C25019F0071 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award